Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies


Authors: B. Dejanovic, M.A. Huntley, A. De Mazière, W.J. Meilandt, T. Wu, K. Srinivasan and M. Sheng et al.

Journal: Neuron

DOI: 10.1016/j.neuron.2018.10.014

Publication - Abstract

November 01, 2018

Neuroscience Nucleic Acid Lipid Nanoparticles siRNA
Synapse loss and Tau pathology are hallmarks of Alzheimer’s disease (AD) and other tauopathies, but how Tau pathology causes synapse loss is unclear. We used unbiased proteomic analysis of postsynaptic densities (PSDs) in Tau-P301S transgenic mice to identify Tau-dependent alterations in synapses prior to overt neurodegeneration. Multiple proteins and pathways were altered in Tau-P301S PSDs, including depletion of a set of GTPase-regulatory proteins that leads to actin cytoskeletal defects and loss of dendritic spines. Furthermore, we found striking accumulation of complement C1q in the PSDs of Tau-P301S mice and AD patients. At synapses, C1q decorated perisynaptic membranes, accumulated in correlation with phospho-Tau, and was associated with augmented microglial engulfment of synapses and decline of synapse density. A C1q-blocking antibody inhibited microglial synapse removal in cultured neurons and in Tau-P301S mice, rescuing synapse density. Thus, inhibiting complement-mediated synapse removal by microglia could be a potential therapeutic target for Tau-associated neurodegeneration.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Summary

Mar 01, 2017
Neuro-Oncology

Immune Modulatory Nanoparticle Therapeutics for Intracerebral Glioma

N.K. Yaghi, J. Wei, Y. Hashimoto, L.Y. Kong, A.B Heimberger et al.

Hematology microRNA Genetic Medicine
Small interfering RNAs (siRNA) and microRNAs (miRNA) have gained a lot of clinical interest in recent years as they can specifically target genes/ proteins of interest and can be engineered to fit the patients’ unique needs and conditions.
Read More


Publication - Abstract

Apr 03, 2016
Nucleic Acids

A Glu-urea-Lys Ligand-Conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression in Vivo

J.B. Lee, K. Zhang, Y.Y. Tam, J. Quick, Y.K. Tam, P.J. Lin, S. Chen, Y. Liu, J.K. Nair, I. Zlatev and K.G. Rajeev

Nucleic Acid Lipid Nanoparticles siRNA Targeted Drug Delivery

The androgen receptor plays a critical role in the progression of prostate cancer. Here, we describe targeting the prostate-specific membrane antigen using a lipid nanoparticle (LNP) formulation containing small interfering RNA (siRNA) designed to ...

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up